SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006362
Filing Date
2021-05-07
Accepted
2021-05-07 07:30:38
Documents
74
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20210331x10q.htm   iXBRL 10-Q 1535780
2 EX-31.1 acrs-20210331xex31d1.htm EX-31.1 15728
3 EX-31.2 acrs-20210331xex31d2.htm EX-31.2 15734
4 EX-32.1 acrs-20210331xex32d1.htm EX-32.1 9510
  Complete submission text file 0001558370-21-006362.txt   7009022

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20210331.xsd EX-101.SCH 47463
6 EX-101.CAL acrs-20210331_cal.xml EX-101.CAL 51416
7 EX-101.DEF acrs-20210331_def.xml EX-101.DEF 177607
8 EX-101.LAB acrs-20210331_lab.xml EX-101.LAB 510120
9 EX-101.PRE acrs-20210331_pre.xml EX-101.PRE 350471
10 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20210331x10q_htm.xml XML 1331875
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 21900250
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences